SS-31 Peptide UK: Elamipretide Evidence in the Peptides UK Market

Direct Answer

SS-31 is the research designation for elamipretide, a four-residue synthetic peptide with the sequence D-Arg-2,6-dimethyl-Tyr-Lys-Phe-NH₂. It contains one D-amino acid, an unusual dimethylated tyrosine residue and a C-terminal amide.

The peptide is attracted to mitochondrial membranes through its alternating positively charged and aromatic structure. It associates with cardiolipin within the inner mitochondrial membrane and can affect membrane organisation, cytochrome-c behaviour, electron transport and ATP-related bioenergetics in experimental systems.

In September 2025, the FDA granted accelerated approval to Forzinity, a defined elamipretide hydrochloride prescription product, to improve muscle strength in adults and children with Barth syndrome weighing at least 30 kilograms.

The original randomised Barth-syndrome trial did not demonstrate superiority over placebo on its primary six-minute walking-distance and fatigue endpoints. The approval relied on increased knee-extensor muscle strength observed during a longer open-label extension, an intermediate endpoint that must be confirmed in further research.

Larger trials in primary mitochondrial myopathy, heart failure and geographic atrophy did not meet their principal efficacy endpoints. Current evidence therefore does not establish SS-31 for healthy ageing, athletic performance, general fatigue, kidney protection, neurological optimisation or routine mitochondrial enhancement.

SS-31 Peptide Key Points

The essential scientific, clinical and regulatory distinctions for readers researching elamipretide and Peptides UK content.

Established name Elamipretide

Research names SS-31 and MTP-131

Earlier development name Bendavia

Peptide length Four amino-acid residues

Primary molecular association Mitochondrial cardiolipin

FDA status Accelerated approval for a narrow Barth-syndrome indication

UK status No marketing authorisation identified

Main evidence warning One disease-specific approval does not validate general wellness use

What Is SS-31 Peptide?

SS-31 is a synthetic mitochondria-associated tetrapeptide now formally known as elamipretide.

The peptide was developed within a family of compounds called Szeto-Schiller peptides. These short peptides contain alternating aromatic and positively charged residues.

SS-31 consists of D-arginine, 2,6-dimethyltyrosine, lysine and phenylalaninamide. The C-terminal phenylalanine is amidated rather than ending with a conventional carboxylic acid.

The dimethyltyrosine residue is often abbreviated to Dmt. It is chemically different from ordinary tyrosine because methyl groups are present at the 2 and 6 positions of its aromatic ring.

The structure is not a naturally occurring human peptide sequence. It was designed to cross cell membranes and associate with mitochondrial membranes without relying on the strongly negative mitochondrial membrane potential in the same way as some lipophilic cation systems.

Plain-English explanation: SS-31 is a laboratory-designed four-amino-acid molecule intended to reach the inner membrane of mitochondria. Its structure allows it to interact with cardiolipin, a specialised membrane lipid involved in energy production.

SS-31, Elamipretide, MTP-131 and Bendavia

Several names describe the same active peptide, but the surrounding product may differ.

Name	Context	Important Distinction
SS-31	Early laboratory and Szeto-Schiller research name	Common in animal, cellular and online peptide discussions
MTP-131	Clinical-development designation	Appears in earlier mitochondrial and cardiovascular publications
Bendavia	Earlier proprietary development name	Used in several cardiovascular and renal research contexts
Elamipretide	Established generic drug name	Preferred name in modern clinical and regulatory sources
Forzinity	FDA-approved prescription product	Defined sterile elamipretide hydrochloride formulation for a restricted indication

These names identify the active peptide lineage, but they do not prove that every product is pharmaceutically equivalent.

The FDA-approved medicine contains elamipretide isolated as a defined hydrochloride salt within a regulated sterile formulation.

Online materials may instead contain a free peptide, trifluoroacetate-associated material, acetate-associated material, another hydrochloride composition or an inaccurately labelled product.

A shared active name does not establish equivalence

A research vial labelled SS-31 should not be presented as generic Forzinity. Equivalence would require extensive evidence concerning identity, salt form, concentration, impurities, stability, sterility, bioavailability and manufacturing controls.

SS-31 Research in the Peptides UK Market

Commercial interest has expanded beyond the narrow setting in which elamipretide has regulatory approval.

SS-31 appears in Peptides UK catalogues alongside MOTS-c, humanin, SS-31 analogues and other compounds associated with mitochondrial research.

Product descriptions commonly associate it with energy, exercise endurance, recovery, reduced fatigue, cardiovascular support, kidney protection, brain health, metabolic health, anti-ageing and cellular repair.

Some descriptions now refer to FDA approval without explaining that the authorised indication concerns Barth syndrome, an exceptionally rare genetic disorder directly involving abnormal cardiolipin metabolism.

The approval does not establish treatment of ordinary tiredness, age-related mitochondrial change, athletic recovery or general metabolic dysfunction.

It also does not authorise products manufactured independently of the approved pharmaceutical supply chain.

FDA approval must not be used out of context

It is misleading to state simply that “SS-31 is FDA approved” without identifying the authorised product, disease, patient group and accelerated-approval conditions.

SS-31 Research and Development History

The compound moved from opioid-receptor peptide research into mitochondria-directed drug development.

Szeto-Schiller Peptide Discovery

Researchers designed short aromatic-cationic peptides and observed that selected sequences entered cells and concentrated near mitochondrial structures.

Mitochondrial Localisation

SS-31 was identified as a peptide capable of associating with the inner mitochondrial membrane and influencing oxidative and bioenergetic measurements.

Cardiolipin Mechanism

Biophysical and animal studies reported high-affinity interaction with cardiolipin and preservation of cristae architecture during mitochondrial stress.

Clinical Development as MTP-131 and Bendavia

Human trials investigated mitochondrial myopathy, cardiovascular disease, age-related macular degeneration and other conditions.

Barth-Syndrome Programme

Elamipretide was studied in patients with genetically confirmed Barth syndrome, a disorder in which cardiolipin remodelling is directly disrupted.

FDA Accelerated Approval

In September 2025, Forzinity became the first FDA-approved treatment for improving muscle strength in patients with Barth syndrome weighing at least 30 kilograms.

SS-31 Molecular and Scientific Profile

The peptide contains non-standard structural features that must be confirmed analytically.

Peptide identity

Elamipretide Free Peptide

D-Arg 2,6-Dmt Lys Phe-NH₂

The peptide sequence is D-Arg-2,6-dimethyl-Tyr-Lys-Phe-NH₂.

Primary membrane association

Cardiolipin-Rich Mitochondrial Membranes

Elamipretide localises to the inner mitochondrial membrane and interacts with cardiolipin-rich membrane environments.

This association can influence membrane electrostatics, protein organisation and mitochondrial bioenergetics.

Established name	Elamipretide
Research designations	SS-31 and MTP-131
Earlier development name	Bendavia
Peptide sequence	D-Arg-2,6-dimethyl-Tyr-Lys-Phe-NH₂
Peptide length	Four residues
Free-peptide molecular formula	C₃₂H₄₉N₉O₅
Approximate free-peptide molecular weight	639.8 g/mol
FDA-approved salt	Elamipretide hydrochloride represented as a trihydrochloride
FDA-approved hydrochloride formula	C₃₂H₄₉N₉O₅·3HCl
Approximate hydrochloride molecular weight	749.2 g/mol
C-terminal structure	Phenylalaninamide
Primary regulatory target description	Mitochondrial cardiolipin binder

Elamipretide Free Peptide, Hydrochloride and Other Salt Forms

Products using the SS-31 name may not contain the same molecular form.

Form	Simplified Description	Important Distinction
Elamipretide free peptide	D-Arg-Dmt-Lys-Phe-NH₂ without specified counterions	Reference basis for the active peptide mass
Elamipretide trihydrochloride	Peptide associated with three hydrochloride equivalents	Salt form used in the FDA-approved prescription product
Elamipretide TFA	Peptide associated with trifluoroacetate	May result from peptide synthesis and purification
Elamipretide acetate	Peptide associated with acetate counterions	Not equivalent automatically to the approved hydrochloride
Modified SS-31 analogues	Peptides containing altered residues or terminal chemistry	Require separate identity, potency and evidence assessment

Elamipretide contains several basic groups and can associate with more than one acid equivalent.

The number and identity of counterions affect molecular weight, net peptide calculations, solubility and formulation behaviour.

A certificate that reports only the free-peptide molecular formula while labelling the product as a salt is incomplete unless the calculation basis is explained.

Salt identity matters

Elamipretide hydrochloride, TFA-associated SS-31 and acetate-associated SS-31 should not be described as analytically identical finished materials.

Why Mitochondria Matter in SS-31 Research

Mitochondria produce cellular energy but also participate in signalling, metabolism and cell-death pathways.

Mitochondria contain an outer membrane and a highly folded inner membrane. The folds of the inner membrane are called cristae.

Respiratory-chain complexes within the inner membrane transfer electrons and help create the electrochemical gradient used by ATP synthase.

ATP is an essential cellular energy carrier, but mitochondrial function extends beyond ATP production. Mitochondria also contribute to calcium handling, lipid metabolism, reactive-oxygen signalling, apoptosis and metabolic integration.

Mitochondrial dysfunction can occur in primary genetic disorders and as a secondary feature of many acquired diseases.

The presence of mitochondrial dysfunction in a disease does not mean that every mitochondria-associated compound will improve the disease clinically.

“Mitochondrial dysfunction” is not one diagnosis

A TAFAZZIN mutation affecting cardiolipin remodelling is biologically different from ordinary tiredness, age-related decline, heart failure, diabetes, medication toxicity or exercise fatigue.

Cardiolipin and the Inner Mitochondrial Membrane

Cardiolipin provides a biologically plausible target for elamipretide.

Cardiolipin is an unusual phospholipid containing four fatty-acid chains. It is concentrated within the inner mitochondrial membrane.

It helps organise respiratory-chain proteins, stabilise membrane curvature and maintain cristae structure.

Cardiolipin interacts with cytochrome c, which normally transfers electrons between respiratory complexes.

During severe oxidative or ischaemic stress, the interaction can change and cytochrome c can acquire peroxidase-like activity capable of oxidising cardiolipin.

Cardiolipin oxidation and membrane disorganisation may impair electron transport, promote mitochondrial permeability changes and contribute to cell injury.

Laboratory studies report that SS-31 associates with cardiolipin through electrostatic and hydrophobic interactions and alters the membrane environment around cardiolipin-binding proteins.

Research interpretation: elamipretide does not replace cardiolipin or correct the underlying TAFAZZIN mutation. It interacts with the existing mitochondrial membrane while the peptide is present.

How Is SS-31 Thought to Work?

The FDA-approved label describes cardiolipin binding, mitochondrial localisation and improvement of mitochondrial morphology and function.

Cardiolipin Association

SS-31 associates preferentially with cardiolipin-containing membranes in several biophysical and experimental systems.

Aromatic residues can enter the membrane interface while positively charged residues interact with the negatively charged lipid environment.

Cytochrome-c Function

Experimental studies report that the SS-31 and cardiolipin interaction can inhibit cytochrome-c peroxidase activity while preserving cytochrome c as an electron carrier.

This may support electron transfer and limit cardiolipin oxidation during selected forms of mitochondrial stress.

Cristae Organisation

Animal and cellular research has reported preservation or restoration of cristae structure after ischaemic, genetic or metabolic injury.

Cristae architecture influences respiratory-chain organisation and ATP synthesis.

Membrane Electrostatics

Later biophysical work suggests that SS-31 can modify the surface electrostatics of mitochondrial and model membranes.

This could influence ions, proteins and lipid-protein interactions at the membrane interface.

Protein Interactions

Cross-linking mass-spectrometry research identified interactions near proteins involved in oxidative phosphorylation and mitochondrial metabolism.

These findings suggest that the mechanism may extend beyond one simple peptide-to-lipid interaction.

Elamipretide enters cells

Associates with cardiolipin-rich inner membranes

Membrane and cytochrome-c interactions change

Cristae and electron transport may stabilise

Clinical effect depends on the disease context

A credible mechanism does not guarantee clinical success

Elamipretide has a more developed mechanistic evidence base than many research peptides. Even so, several well-designed clinical trials did not meet their primary endpoints.

SS-31 and Barth Syndrome

Barth syndrome is the condition in which cardiolipin-directed treatment has the strongest biological rationale.

Barth syndrome is a rare X-linked genetic disorder caused by pathogenic variants in the TAFAZZIN gene.

TAFAZZIN is involved in cardiolipin remodelling. Abnormal remodelling alters cardiolipin composition and increases the relationship between monolysocardiolipin and mature cardiolipin.

The disorder can involve skeletal-muscle weakness, cardiomyopathy, exercise intolerance, growth problems and neutropenia.

Because the molecular disorder directly affects cardiolipin biology, Barth syndrome is more closely aligned with the proposed action of elamipretide than general conditions in which mitochondrial changes are secondary.

This does not mean that elamipretide repairs the genetic defect or normalises cardiolipin synthesis permanently.

Barth-syndrome evidence cannot be generalised broadly

A clinical effect in a rare genetic cardiolipin disorder does not establish benefits for healthy people or for unrelated conditions described loosely as mitochondrial dysfunction.

FDA Accelerated Approval of Elamipretide

The approval is real but narrow, conditional and based on an intermediate endpoint.

Approved United States Indication

Forzinity is FDA approved to improve muscle strength in adult and paediatric patients with Barth syndrome who weigh at least 30 kilograms.

The approval was granted on 19 September 2025 through the accelerated-approval pathway.

Continued approval may depend on verification and description of clinical benefit in a confirmatory trial.

What Accelerated Approval Means

Accelerated approval can allow earlier access to medicines for serious conditions based on an intermediate or surrogate endpoint considered reasonably likely to predict clinical benefit.

It does not mean that uncertainty has disappeared or that every proposed benefit has been confirmed.

The sponsor must complete additional research to verify the predicted clinical benefit.

What the Approval Does Not Cover

Healthy ageing
Athletic performance
General fatigue
Exercise recovery
Primary mitochondrial myopathy generally
Heart failure
Age-related macular degeneration
Kidney disease
Parkinson’s disease
Metabolic syndrome
Weight loss
Cognitive enhancement
General mitochondrial optimisation
Research-market SS-31 products

What Evidence Supported the FDA Approval?

The trial record is more nuanced than a simple statement that the drug “worked”.

Randomised Crossover Phase

The pivotal Barth-syndrome programme involved 12 participants with genetically confirmed disease.

The randomised, double-blind crossover phase compared elamipretide with placebo.

The primary endpoints were distance walked during the six-minute walk test and the total fatigue score on a Barth-syndrome symptom assessment.

Elamipretide was not superior to placebo on those two primary endpoints.

Open-Label Extension

Ten participants entered a longer single-arm extension, and eight remained through 168 weeks.

Increases in knee-extensor muscle strength were observed during the extension period.

The FDA treated knee-extensor strength as an intermediate clinical endpoint supporting accelerated approval.

Why Interpretation Requires Caution

An open-label extension has no concurrent placebo group and can be affected by participant selection, training, natural variation, supportive care and repeated testing.

The participant number was exceptionally small because Barth syndrome is ultra rare.

The FDA concluded that the strength changes were sufficient to support accelerated access while requiring confirmatory evidence.

Primary endpoints were not met in the randomised portion

Responsible reporting should include this fact rather than presenting the approval as the result of an unequivocally positive large randomised trial.

Why a Confirmatory Elamipretide Trial Is Required

The post-marketing study is intended to verify that the muscle-strength endpoint predicts meaningful clinical benefit.

The FDA’s ongoing accelerated-approval requirements list a randomised, double-blind, placebo-controlled confirmatory study in people aged five years and older with Barth syndrome.

The study is expected to evaluate knee-extensor muscle strength and describe the clinical benefit associated with treatment.

The current FDA schedule lists completion of the post-marketing requirement in 2030.

Confirmatory research may support the existing indication, refine it or reveal limitations not apparent in the small original programme.

Regulatory interpretation: accelerated approval provides legal prescription access in the United States while confirmatory evidence is still being generated.

SS-31 Research in Primary Mitochondrial Myopathy

Early signals did not translate into a positive phase-three result across the full study population.

Early Dose-Escalation Study

A randomised dose-escalation study enrolled adults with genetically confirmed primary mitochondrial myopathy.

Selected exercise measurements suggested a possible short-term signal, but the trial was exploratory and not sufficient to establish treatment.

MMPOWER-2

A randomised crossover trial involving 30 participants compared elamipretide with placebo.

The difference in six-minute walking distance did not reach statistical significance as the primary endpoint.

Several patient-reported fatigue measures favoured elamipretide and supported progression to a larger trial.

MMPOWER-3

The larger phase-three trial assessed elamipretide over 24 weeks in people with primary mitochondrial myopathy.

The trial provided high-level evidence that elamipretide did not improve the six-minute walk test or fatigue compared with placebo across the overall enrolled population.

Post-Hoc Genetic Analysis

Later exploratory analysis suggested that responses may differ between genetic subgroups.

Post-hoc findings can generate hypotheses, but they do not reverse a negative overall trial or establish effectiveness in a newly selected group without prospective confirmation.

Mitochondrial diseases are genetically diverse

A treatment may interact differently with defects affecting mitochondrial DNA, nuclear genes, cardiolipin, respiratory complexes or mitochondrial maintenance. A broad mitochondrial label can hide important biological differences.

SS-31 and Heart-Failure Research

Clinical heart-failure research did not establish elamipretide as an approved cardiac treatment.

Single-Infusion Study

An early ascending-dose study investigated a short intravenous infusion in people with heart failure and reduced ejection fraction.

Selected ventricular measurements changed at the highest studied exposure, providing a rationale for further investigation.

PROGRESS-HF Trial

The phase-two PROGRESS-HF trial evaluated repeated elamipretide exposure in patients with stable heart failure and reduced ejection fraction.

Elamipretide was generally tolerated but did not improve the principal left-ventricular end-systolic-volume endpoint compared with placebo after four weeks.

Preclinical Versus Clinical Evidence

Dog and rodent models have reported improvements in mitochondrial and ventricular measurements.

Animal heart-failure models do not reproduce every cause, medicine combination and clinical outcome present in human heart failure.

Not an authorised heart-failure medicine

SS-31 should not replace guideline-directed heart-failure treatment or be presented as a clinically established mitochondrial therapy for heart disease.

Elamipretide and Age-Related Macular Degeneration

Early exploratory findings were followed by a larger phase-two trial that missed its primary endpoints.

ReCLAIM Phase-One Studies

Early studies investigated elamipretide in dry age-related macular degeneration and related retinal conditions.

The compound appeared generally tolerated, and exploratory visual or structural signals supported larger research.

ReCLAIM-2

The randomised, double-masked, placebo-controlled ReCLAIM-2 trial enrolled people with non-central geographic atrophy.

The trial did not meet its primary endpoints involving low-luminance best-corrected visual acuity and geographic-atrophy progression.

Exploratory structural measurements involving the ellipsoid zone suggested possible biological activity.

Exploratory secondary or imaging findings cannot substitute for missed primary endpoints without prospective confirmation.

Elamipretide is not an FDA- or UK-authorised treatment for dry age-related macular degeneration.

SS-31 Research in Older Adult Skeletal Muscle

A small mechanistic study reported a temporary bioenergetic change rather than proven rejuvenation.

A randomised study examined mitochondrial ATP production in older adults following a single elamipretide exposure.

The investigators reported increased maximal mitochondrial ATP production in skeletal muscle.

The effect was measured through specialised metabolic testing and did not establish longer-term improvement in strength, endurance, disability, frailty or lifespan.

A short-lived bioenergetic response after one exposure should not be presented as reversal of mitochondrial ageing.

Healthy ageing involves muscle mass, neuromuscular function, cardiovascular capacity, nutrition, activity, inflammation and many other systems.

ATP measurement is not an anti-ageing outcome

Improving a laboratory measure temporarily does not demonstrate that a person becomes biologically younger or experiences a meaningful long-term functional benefit.

SS-31 Kidney and Ischaemia Research

The strongest kidney findings are preclinical and should not be presented as established human renal treatment.

Cardiolipin oxidation and cristae disruption occur during severe renal ischaemia and reperfusion in experimental systems.

Rat studies reported that SS-31 preserved mitochondrial cristae, accelerated ATP recovery and reduced selected markers of acute kidney injury.

Mouse models have also examined ageing-related renal changes, obesity-associated kidney injury, diabetic kidney injury and cisplatin-associated damage.

These models differ from chronic kidney disease, medication-related nephrotoxicity and acute kidney injury in heterogeneous human patients.

No current UK or FDA approval was identified for kidney protection, improvement of estimated glomerular filtration rate or treatment of renal disease.

Do not convert animal kidney findings into personal-use claims

Changes in creatinine or filtration measurements can reflect hydration, muscle mass, laboratory variation and many medical conditions. Experimental peptide use should not replace clinical renal assessment.

SS-31 Neurological and Neurodegeneration Research

Laboratory and animal findings remain distinct from established human neurological treatment.

Mitochondrial dysfunction is investigated in Parkinson’s disease, Alzheimer’s disease, epilepsy, stroke and other neurological conditions.

Cell and animal studies have examined SS-31 in models involving alpha-synuclein, oxidative injury, ferroptosis, seizures and ischaemia.

Recent laboratory research reported that SS-31 altered alpha-synuclein membrane interaction and mitochondrial dysfunction under experimental conditions.

Rat epilepsy models have reported changes in ferroptosis-related and inflammatory pathways.

These findings do not establish cognitive enhancement, neuroprotection or treatment of Parkinson’s disease, epilepsy, stroke or dementia in people.

A shared mitochondrial feature does not establish a shared treatment

Neurological disorders differ in cause, affected cells, disease stage and pathological proteins. A mitochondrial mechanism alone is insufficient to demonstrate clinical efficacy.

What Evidence Supports SS-31 in Healthy People?

No robust clinical programme establishes routine use for healthy-person energy, performance, recovery or longevity.

Most controlled elamipretide trials enrolled people with diagnosed mitochondrial, cardiac, retinal or rare genetic disease.

A small mechanistic study in older adults does not establish general use in younger healthy adults or athletes.

No large randomised trial was identified demonstrating improved sports performance, muscle growth, recovery time, cognition, healthy lifespan or resistance to ordinary fatigue.

Exercise adaptations depend partly on temporary oxidative and metabolic signals. It should not be assumed that modifying mitochondrial redox conditions improves every training response.

The approved medicine also has recognised adverse reactions and requires medical oversight.

No established “mitochondrial optimisation” indication

The phrase is commercially attractive but medically undefined. There is no validated clinical endpoint showing that healthy people require routine cardiolipin-targeted treatment.

SS-31 Peptide Evidence at a Glance

The evidence varies greatly by disease, study design and endpoint.

Research Question	Evidence Type	Current Finding	Main Limitation
Does SS-31 associate with cardiolipin?	Biophysical, cellular and animal research	Strong evidence of membrane association	Mechanism alone does not predict every clinical outcome
Can it affect mitochondrial morphology?	Cell and animal studies plus FDA pharmacology assessment	Changes reported in stressed or abnormal mitochondria	Effect depends on disease and tissue context
Is elamipretide FDA approved?	FDA regulatory approval	Yes, for improving muscle strength in selected Barth-syndrome patients	Accelerated and narrowly restricted approval
Did the randomised Barth trial meet its primary endpoints?	Randomised crossover trial	No	Approval relied on an intermediate endpoint from the extension
Was muscle strength improved during the extension?	Small open-label extension	Increases in knee-extensor strength were observed	No concurrent placebo and very small group
Is confirmatory research required?	FDA post-marketing requirement	Yes	Clinical benefit remains to be verified formally
Does it treat primary mitochondrial myopathy broadly?	Phase-three randomised trial	Primary walking and fatigue endpoints were not improved	Possible genetic-subgroup hypotheses remain exploratory
Does it improve heart failure?	Phase-two randomised trial	Principal ventricular endpoint was not improved	Short duration and selected population
Does it treat dry AMD?	Phase-two randomised trial	Primary visual and atrophy endpoints were not met	Exploratory imaging signals require confirmation
Does it improve mitochondrial ATP production in older muscle?	Small mechanistic human trial	Temporary bioenergetic increase reported	No established long-term functional benefit
Does it protect human kidneys?	Mainly animal and cellular studies	Preclinical protection reported	No authorised clinical renal indication
Does it improve healthy-person performance?	Clinical evidence	Not established	No robust healthy-athlete programme
Is it authorised in the UK?	Official UK-source review	No marketing authorisation identified	An MHRA paediatric plan is not marketing approval

Important SS-31 Research Limitations

Regulatory approval in one rare disease should not obscure the mixed wider clinical record.

The approved Barth-syndrome population is extremely small.
The randomised Barth trial did not meet its primary walking-distance endpoint.
The randomised Barth trial did not meet its primary fatigue endpoint.
Accelerated approval relied on an intermediate muscle-strength endpoint.
The key strength improvements arose during an open-label extension.
Only eight participants remained through week 168 of that extension.
A confirmatory randomised study remains required.
Primary mitochondrial myopathy is genetically heterogeneous.
MMPOWER-3 did not meet its principal overall efficacy endpoints.
Genotype-specific analyses were post hoc.
PROGRESS-HF did not meet its primary ventricular endpoint.
ReCLAIM-2 did not meet either primary endpoint.
Exploratory secondary findings can generate hypotheses but not approvals.
Many kidney findings come from rodents.
Many neurological findings come from cells or animal models.
A temporary ATP-production change is not evidence of rejuvenation.
No robust healthy-athlete trial was identified.
No human-longevity trial was identified.
Barth syndrome is not representative of ordinary mitochondrial ageing.
Research-market products may use different salt forms.
Online products are not demonstrated to be equivalent to Forzinity.
Injection-site reactions are common in the approved clinical programme.
Serious hypersensitivity reactions have been reported.
Renal impairment materially changes drug exposure.
Long-term carcinogenicity studies have not been conducted.
No current UK marketing authorisation was identified.

How SS-31 Research Material Should Be Analytically Tested

Testing must confirm the D-amino acid, dimethyltyrosine, amidated terminus and exact salt composition.

Identity

Intact Molecular Mass

High-resolution mass spectrometry should support the mass of the declared elamipretide form.

Sequence

Tandem Mass Spectrometry

Fragment-ion evidence should support D-Arg-Dmt-Lys-Phe-NH₂.

Stereochemistry

D-Arginine Confirmation

Chiral or validated stereochemical analysis should distinguish D-arginine from an all-L peptide.

Modified residue

2,6-Dimethyltyrosine Identity

Testing should confirm dimethyltyrosine rather than ordinary tyrosine or another aromatic residue.

Terminal group

C-Terminal Amidation

The phenylalaninamide terminus should be distinguished from a free carboxylic-acid form.

Salt form

Counterion Analysis

Hydrochloride, trifluoroacetate and acetate content should be identified and quantified.

Quantity

Net Elamipretide Assay

Active-peptide quantity should be measured independently of water, salts and excipients.

Impurities

Related-Substance Profiling

Testing should assess deletion sequences, epimers, incomplete amidation and synthesis-related impurities.

What a Meaningful SS-31 Certificate of Analysis Should Include

Established name elamipretide
Research name SS-31 where relevant
Complete D-Arg-2,6-dimethyl-Tyr-Lys-Phe-NH₂ sequence
Confirmation of D-arginine stereochemistry
Confirmation of the dimethyltyrosine residue
Confirmation of C-terminal amidation
Declared free-peptide or salt form
Observed intact molecular mass
Tandem-MS sequence evidence
Chiral or stereochemical identity evidence
Quantitative net peptide assay
Chromatographic purity
Named and unknown impurity results
Counterion content
Water-content result
Residual-solvent results
Elemental-impurity results where appropriate
Aggregate or higher-molecular-weight-species assessment
Finished-product stability information
Batch number and testing-laboratory identity
Analytical methods and acceptance criteria
A clear statement of tests not performed

Why “99% HPLC” Is Not Enough

A chromatographic percentage does not prove the correct stereochemistry, dimethyltyrosine structure or C-terminal amide.

It also does not establish salt content, active-peptide quantity, aggregation, sterility, endotoxin control or equivalence to the FDA-approved product.

A synthesis impurity can have a similar retention time while differing in residue configuration or terminal chemistry.

The approved prescription product sets a much higher standard

A research certificate reporting mass and HPLC purity is not equivalent to an approved medicine’s complete chemistry, manufacturing, controls, stability, sterility and pharmacovigilance programme.

SS-31 Safety and Adverse-Reaction Evidence

The approved prescribing information provides more reliable safety data than online anecdotal reports.

Injection-Site Reactions

Injection-site reactions were the most frequent adverse reactions in the Barth-syndrome clinical programme.

Reported reactions included redness, pain, induration, itching, bruising and urticaria.

Every elamipretide-treated participant in the controlled Barth study experienced at least one local administration reaction.

Hypersensitivity

Serious allergic reactions requiring emergency medical intervention have been reported with the approved medicine.

The FDA label lists serious hypersensitivity as a contraindication to further use.

Eosinophilia

Increases in eosinophil counts were observed frequently in studies lasting 30 days or longer.

Counts generally returned towards baseline during continued exposure or after discontinuation, and the increases were not linked with clinical manifestations in the reported programme.

Renal Function

Elamipretide and its inactive peptide metabolites are excreted through urine.

Drug exposure rises as renal function declines, with particularly substantial increases in the M1 and M2 metabolites during severe renal impairment.

This demonstrates why a compound marketed for “kidney support” can require additional caution in people with kidney impairment.

Benzyl Alcohol in the Approved Product

Forzinity contains benzyl alcohol as a preservative and is not approved for neonates.

The preservative warning applies to the authorised formulation and should not be confused with the active peptide itself.

Pregnancy and Lactation

Human pregnancy and breastfeeding data are absent or inadequate.

Barth syndrome is X-linked and primarily affects males, which limits pregnancy data within the indicated population.

Carcinogenicity and Genotoxicity

Long-term carcinogenicity studies have not been conducted with elamipretide.

The approved label reports negative findings in several standard bacterial, cellular and rodent genotoxicity assays.

Research-Product Risks

Incorrect peptide identity
Incorrect stereochemistry
Ordinary tyrosine substituted for dimethyltyrosine
Absent C-terminal amidation
Incorrect salt form
Incorrect active-peptide quantity
Peptide-related impurities
Residual synthesis reagents
Residual organic solvents
Aggregates
Unverified sterility
Unverified bacterial-endotoxin control
Incorrect excipients
Certificates unrelated to the supplied batch
Uncontrolled shipping and storage

Prescription safety data do not validate grey-market products

The safety profile of a regulated formulation cannot be transferred to an independently manufactured vial with unknown composition, contaminants, concentration or microbiological quality.

SS-31 Regulation in the Peptides UK Market

Regulatory position reviewed on 22 July 2026.

No Current UK Marketing Authorisation Identified

No current UK marketing authorisation for an elamipretide medicinal product was identified in the official UK sources searched for this article.

The MHRA has published an agreed paediatric investigation plan concerning elamipretide for Barth syndrome.

A paediatric investigation plan concerns the development of age-appropriate evidence. It does not authorise sale, advertising or routine prescribing.

United States Approval Does Not Create UK Approval

FDA authorisation applies within the United States and under the conditions stated in the approved prescribing information.

A company seeking UK authorisation must satisfy the relevant UK requirements for quality, safety and efficacy.

A seller cannot rely solely on FDA approval to market an unauthorised SS-31 product as a medicine in the United Kingdom.

How the MHRA Assesses Product Status

MHRA guidance states that a product may be medicinal when it is presented as treating or preventing disease.

It may also be medicinal when intended to restore, correct or modify physiological functions through pharmacological, immunological or metabolic action.

Claims concerning mitochondrial disease, fatigue, heart failure, kidney disease, exercise recovery, ageing, ATP production or cellular repair could contribute to medicinal classification.

The MHRA can consider labels, website text, images, customer reviews, social-media posts, instructions and the overall commercial presentation.

Research-Use Wording

A “Research Use Only” label does not settle the legal position where the wider presentation encourages administration or promises physiological benefits.

Advertising Restrictions

Regulation 279 of the Human Medicines Regulations restricts advertising medicinal products where the required authorisation, registration or certificate is not in force.

This section provides general regulatory education rather than legal advice.

SS-31 and Competitive Sport

The FDA approval changes the analysis of the broad non-approved-substance rule, but athletes still need a current product-specific check.

Elamipretide was not identified by name in the 2026 World Anti-Doping Agency Prohibited List reviewed for this article.

WADA’s S0 category concerns pharmacological substances without current approval by any governmental regulatory health authority for human therapeutic use.

Because elamipretide now has FDA approval, it should not automatically be classified as globally unapproved solely under that wording.

This does not guarantee that every formulation, method, combination or future rule interpretation is permitted.

Intravenous methods, additional ingredients and other substances used alongside SS-31 can create separate anti-doping issues.

Athletes should obtain an up-to-date ruling from UK Anti-Doping, Global DRO or the relevant international federation.

Common SS-31 Peptide Claims Examined

Commercial claims often expand one narrow approval into unsupported general mitochondrial promises.

The claim

“SS-31 is FDA approved for mitochondrial health.”

A defined elamipretide prescription product is FDA approved.

The indication is limited to improving muscle strength in Barth-syndrome patients weighing at least 30 kilograms.

The claim

“FDA approval proves every SS-31 vial works.”

Approval applies to a specific product manufactured under regulated pharmaceutical controls.

It does not validate independently manufactured research-market products.

The claim

“The pivotal trial clearly beat placebo.”

The randomised Barth trial did not show superiority on its primary walking and fatigue endpoints.

Accelerated approval relied on muscle-strength improvements observed during the longer open-label extension.

The claim

“SS-31 repairs damaged mitochondria permanently.”

Research reports improved morphology and function while interacting with mitochondrial membranes.

It does not repair mitochondrial DNA mutations or permanently replace abnormal cardiolipin metabolism.

The claim

“SS-31 increases ATP in everyone.”

Bioenergetic changes have been reported in selected cells, animals and a small older-adult study.

Clinical effects vary, and several large disease trials did not meet their primary endpoints.

The claim

“SS-31 cures mitochondrial disease.”

Elamipretide is approved for a specific functional outcome in Barth syndrome.

It does not correct the underlying genetic mutation, and the phase-three primary mitochondrial myopathy trial was negative overall.

The claim

“SS-31 is proven for heart failure.”

Animal and early human studies supplied a plausible rationale.

PROGRESS-HF did not improve its primary ventricular endpoint compared with placebo.

The claim

“SS-31 prevents age-related vision loss.”

ReCLAIM-2 investigated geographic atrophy.

The trial missed its primary visual-function and atrophy-progression endpoints.

The claim

“SS-31 reverses ageing.”

Studies have investigated mitochondrial function in older cells, animals and a small older-adult group.

No human trial established reversal of ageing, frailty or mortality risk.

The claim

“SS-31 improves athletic recovery.”

Mitochondria are central to exercise metabolism.

No robust trial establishes SS-31 as a safe or effective performance or recovery intervention in healthy athletes.

The claim

“SS-31 protects the kidneys.”

Multiple animal studies report protection in experimental renal injury.

No authorised human kidney indication was identified, and renal impairment increases elamipretide exposure.

The claim

“A 99% HPLC certificate proves pharmaceutical quality.”

HPLC purity is one chemical measurement.

It does not establish stereochemistry, dimethyltyrosine identity, amidation, salt composition, sterility or equivalence to Forzinity.

SS-31 Compared With Related Mitochondrial Compounds

Shared mitochondrial marketing does not mean shared structure, mechanism or evidence.

Compound	Basic Identity	Main Research Context	Important Distinction
SS-31 or elamipretide	Modified aromatic-cationic tetrapeptide	Cardiolipin and mitochondrial inner-membrane research	FDA-approved only for a narrow Barth-syndrome indication
MOTS-c	Mitochondrial-genome-derived peptide	Metabolic signalling and exercise research	Different sequence, origin and mechanism
Humanin	Mitochondria-associated peptide sequence	Cell-survival and metabolic research	No equivalence to cardiolipin-binding SS-31
SS-20	Related Szeto-Schiller peptide	Mitochondrial and oxidative-stress models	Different sequence and pharmacology
Coenzyme Q10	Lipid-soluble electron carrier	Electron transport and deficiency states	Not a peptide and has different clinical evidence
Idebenone	Synthetic benzoquinone	Selected mitochondrial and neurological disorders	Small molecule rather than a cardiolipin-binding peptide
TAFAZZIN gene therapy	Experimental genetic intervention	Correction of the underlying Barth-syndrome defect	Targets the causal gene rather than stabilising existing membranes
Nicotinamide riboside	Vitamin B3-related NAD precursor	NAD metabolism and ageing research	Different target and human evidence base

How to Assess SS-31 and Peptides UK Evidence Critically

Use this checklist before accepting scientific, regulatory or product-quality claims.

Does the source use the established name elamipretide?
Is SS-31 being distinguished from the approved product?
Is the full D-Arg-Dmt-Lys-Phe-NH₂ sequence stated?
Is D-arginine stereochemistry confirmed?
Is 2,6-dimethyltyrosine confirmed?
Is C-terminal amidation confirmed?
Is the salt form identified?
Is the product hydrochloride, TFA or acetate associated?
Was net active-peptide quantity measured?
Does the certificate match the finished vial?
Was the study performed in cells, animals or humans?
Did participants have Barth syndrome?
Was the disease caused directly by abnormal cardiolipin metabolism?
Was the trial randomised and placebo controlled?
Did the primary endpoint reach statistical significance?
Did the finding arise only during an open-label extension?
How many participants remained at long-term follow-up?
Was the endpoint intermediate or directly clinical?
Is confirmatory research still required?
Is a post-hoc subgroup being presented as confirmed evidence?
Is an animal kidney result being converted into a human claim?
Is a temporary ATP measurement being called rejuvenation?
Is FDA approval being represented as UK approval?
Is the authorised Barth indication stated accurately?
Are injection-site and hypersensitivity risks acknowledged?
Is renal impairment considered?
Is the source selling the product it describes?

Medical and Editorial Review

This final article has been medically and editorially reviewed for scientific accuracy, patient-safety context, regulatory clarity and responsible interpretation of the available evidence.

Medically reviewed by

Dr Rimas Geiga

The medical review covered mitochondrial bioenergetics, cardiolipin biology, ATP-related claims, metabolic interpretation and clinical-trial endpoints.

Medically reviewed by

Dr Snieguole Geige

The medical review covered Barth-syndrome terminology, adverse reactions, patient-safety wording and the distinction between approved and investigational uses.

Medically reviewed by

Dr Laura Geige

The medical review covered FDA accelerated-approval language, UK regulatory clarity, responsible advertising and the boundaries between authorised medicines and research products.

Editorially reviewed by

It’s Me & You Clinic Editorial Team

The editorial review verified SS-31 naming, chemical forms, trial hierarchy, analytical terminology, source attribution and balanced interpretation of the mixed clinical evidence.

SS-31 Peptide UK Frequently Asked Questions

Evidence-led answers about elamipretide identity, mitochondrial research, FDA approval, safety and UK regulation.

What is SS-31 peptide?

SS-31 is an early research name for elamipretide, a synthetic four-residue peptide designed to associate with the inner mitochondrial membrane.

Is SS-31 the same as elamipretide?

Yes. SS-31, MTP-131 and elamipretide refer to the same active peptide lineage.

What was Bendavia?

Bendavia was an earlier proprietary development name used for elamipretide in cardiovascular and mitochondrial research.

What is the SS-31 sequence?

Its sequence is D-Arg-2,6-dimethyl-Tyr-Lys-Phe-NH₂.

Is SS-31 a naturally occurring peptide?

No. It is a synthetic peptide containing D-arginine, modified tyrosine and a C-terminal amide.

What is cardiolipin?

Cardiolipin is a four-acyl-chain phospholipid concentrated in the inner mitochondrial membrane, where it supports cristae organisation and respiratory-chain function.

How does elamipretide interact with mitochondria?

It associates with cardiolipin-rich mitochondrial membranes and can influence membrane electrostatics, cytochrome-c behaviour, cristae structure and bioenergetic function.

Is SS-31 FDA approved?

A specific elamipretide prescription product is FDA approved under the brand name Forzinity for improving muscle strength in selected patients with Barth syndrome.

What is the exact FDA-approved indication?

It is approved for adults and children with Barth syndrome who weigh at least 30 kilograms, specifically to improve muscle strength.

Was the approval accelerated?

Yes. The FDA granted accelerated approval based on an intermediate muscle-strength endpoint, with confirmatory research required.

Did the randomised Barth trial meet its primary endpoints?

No. Elamipretide was not superior to placebo on the primary six-minute walk and fatigue endpoints.

Why was the medicine approved?

Increased knee-extensor muscle strength was observed during the longer open-label extension, and the FDA accepted this as an intermediate endpoint reasonably likely to predict benefit.

Is a confirmatory trial still required?

Yes. Continued approval may depend on verification and description of clinical benefit in a randomised confirmatory study.

Is online SS-31 the same as Forzinity?

No equivalence should be assumed. The approved medicine has a defined hydrochloride salt, sterile formulation, concentration, manufacturing process and regulatory quality system.

Is SS-31 approved for primary mitochondrial myopathy?

No. The phase-three MMPOWER-3 trial did not improve the primary walking-distance or fatigue outcomes across the overall population.

Does SS-31 treat heart failure?

No approved heart-failure indication exists. PROGRESS-HF did not improve its principal ventricular endpoint compared with placebo.

Does SS-31 treat dry macular degeneration?

No. ReCLAIM-2 did not meet its primary visual-function or geographic-atrophy endpoints.

Does SS-31 increase ATP?

Increased ATP-related bioenergetic measurements have been reported in experimental systems and a small older-adult study. This does not prove a general clinical benefit.

Does SS-31 reverse mitochondrial ageing?

No human trial has established reversal of mitochondrial ageing, frailty or biological age.

Does SS-31 improve athletic performance?

No robust clinical evidence establishes safe or effective use for athletic performance or exercise recovery in healthy people.

Does SS-31 protect the kidneys?

Kidney-protective effects have been reported mainly in animal and cellular models. No approved clinical renal indication was identified.

What are the recognised elamipretide adverse reactions?

Injection-site reactions are most common. Serious hypersensitivity reactions and increases in eosinophil counts have also been reported.

Does kidney function affect elamipretide exposure?

Yes. Exposure to elamipretide and its metabolites rises as renal function declines.

Is SS-31 approved in the UK?

No current UK marketing authorisation was identified in the official sources reviewed.

What is the UK paediatric investigation plan?

The MHRA has agreed a development plan concerning elamipretide in children with Barth syndrome. This is not a marketing authorisation.

Does US approval permit SS-31 marketing in the UK?

No. FDA approval does not replace UK medicine-authorisation and advertising requirements.

Does “Research Use Only” settle the UK legal position?

No. The MHRA may consider claims, intended purpose, ingredient properties, imagery, instructions and the overall commercial presentation.

Is SS-31 prohibited in competitive sport?

It was not identified by name on the reviewed 2026 WADA list. Because elamipretide now has governmental therapeutic approval, the broad S0 analysis has changed, but athletes should obtain a current product-specific ruling.

Does 99% HPLC prove an SS-31 vial is authentic?

No. It does not prove D-arginine stereochemistry, dimethyltyrosine identity, C-terminal amidation, salt form, quantity or sterile quality.

What should an SS-31 certificate include?

It should include intact mass, complete sequence, stereochemistry, modified-residue identity, amidation, salt form, peptide assay, impurity profile, counterions, water, aggregation and batch information.

Does this article provide injection or dosing instructions?

No. It does not provide preparation, reconstitution, injection, infusion, dosing, cycling, stacking or self-experimentation guidance.

Key Takeaways

SS-31 is the research name for the synthetic tetrapeptide elamipretide.
Its sequence is D-Arg-2,6-dimethyl-Tyr-Lys-Phe-NH₂.
It is also known historically as MTP-131 and Bendavia.
Elamipretide associates with cardiolipin in the inner mitochondrial membrane.
A defined elamipretide medicine received FDA accelerated approval in September 2025.
The approval concerns improving muscle strength in Barth-syndrome patients weighing at least 30 kilograms.
The randomised Barth trial did not meet its primary walking or fatigue endpoints.
Approval relied on knee-extensor strength observed during a small open-label extension.
A confirmatory randomised trial remains required.
MMPOWER-3 did not establish broad effectiveness in primary mitochondrial myopathy.
PROGRESS-HF did not meet its principal heart-failure endpoint.
ReCLAIM-2 did not meet its primary geographic-atrophy endpoints.
Kidney, neurological and anti-ageing claims rely mainly on preclinical or mechanistic research.
No robust healthy-person performance or longevity benefit has been established.
Research-market SS-31 is not equivalent automatically to the approved prescription medicine.
Injection-site reactions and hypersensitivity are recognised risks.
No current UK marketing authorisation was identified.
A purity percentage alone cannot establish stereochemistry, salt form, sterility or pharmaceutical equivalence.

Relevant It’s Me & You Clinic Peptides UK Resources

Explore related evidence-led articles and clinical contributor profiles.

MOTS-c Peptide UK

Compare elamipretide’s cardiolipin association with a separate mitochondrial-genome-derived research peptide.

Glutathione Peptide UK

Compare a mitochondrial membrane-targeted peptide with an endogenous tripeptide involved in cellular redox regulation.

Read related redox peptide research

Research Peptides UK

Browse the wider educational series on peptide identity, clinical evidence, analytical testing and UK regulation.

Browse the Peptides UK education library

Dr Rimas Geiga

Learn more about the clinic’s evidence-led approach to metabolism, mitochondrial biology and scientific health education.

View Dr Rimas Geiga’s profile

References

US Food and Drug Administration. FDA grants accelerated approval to first treatment for Barth syndrome. 19 September 2025. FDA approval announcement
US Food and Drug Administration. Forzinity, elamipretide, prescribing information. Revised September 2025. FDA prescribing information
US Food and Drug Administration. Drug Trials Snapshot: Forzinity. Updated 13 May 2026. FDA trial summary
US Food and Drug Administration. Forzinity approval letter, NDA 215244. FDA approval letter
US Food and Drug Administration. Integrated review for elamipretide, NDA 215244. FDA integrated review
US Food and Drug Administration. Ongoing accelerated approvals for non-malignant disorders. FDA confirmatory-trial requirement
PubChem. Elamipretide, CID 11764719. PubChem compound record
Medicines and Healthcare products Regulatory Agency. Paediatric investigation plan MHRA-101705-PIP01-24: elamipretide for treatment of Barth syndrome. MHRA paediatric plan
European Medicines Agency. Orphan designation EU/3/21/2430 for elamipretide in Barth syndrome. EMA orphan-designation record
Birk AV, Liu S, Soong Y, et al. The mitochondrial-targeted compound SS-31 re-energizes ischemic mitochondria by interacting with cardiolipin. Journal of the American Society of Nephrology. 2013;24(8):1250–1261. PMID: 23813215. PubMed record
Birk AV, Chao WM, Bracken C, Warren JD, Szeto HH. Targeting mitochondrial cardiolipin and the cytochrome-c/cardiolipin complex to promote electron transport and optimise ATP synthesis. British Journal of Pharmacology. 2014;171(8):2017–2028. PMID: 24134698. PubMed record
Mitchell W, Ng EA, Tamucci JD, et al. The mitochondria-targeting peptide SS-31 binds lipid bilayers and modulates surface electrostatics as a key component of its mechanism. Journal of Biological Chemistry. 2020. PMID: 32273339. PubMed record
Chavez JD, Tang X, Campbell MD, et al. Mitochondrial protein interaction landscape of SS-31. Proceedings of the National Academy of Sciences. 2020;117(26):15363–15373. PMID: 32554501. PubMed record
Reid Thompson W, Hornby B, Manuel R, et al. A phase 2/3 randomized clinical trial followed by an open-label extension to evaluate elamipretide in Barth syndrome. Genetics in Medicine. 2021. PMID: 33077895. PubMed record
Hornby B, et al. Long-term efficacy and safety of elamipretide in patients with Barth syndrome: 168-week open-label extension results. 2024. PMID: 38602181. PubMed record
Karaa A, Haas R, Goldstein A, et al. Randomized dose-escalation trial of elamipretide in adults with primary mitochondrial myopathy. Neurology. 2018. PMID: 29500292. PubMed record
Karaa A, Haas R, Goldstein A, et al. A randomized crossover trial of elamipretide in adults with primary mitochondrial myopathy. Journal of Cachexia, Sarcopenia and Muscle. 2020;11(4):909–918. PMID: 32096613. PubMed record
Karaa A, et al. Efficacy and safety of elamipretide in individuals with primary mitochondrial myopathy: the MMPOWER-3 randomized clinical trial. 2023. PMID: 37268435. PubMed record
Karaa A, et al. Genotype-specific effects of elamipretide in primary mitochondrial myopathy: post-hoc analysis of MMPOWER-3. 2024. PMID: 39574155. PubMed record
Daubert MA, Yow E, Dunn G, et al. Novel mitochondria-targeting peptide in heart-failure treatment: a randomized placebo-controlled trial of elamipretide. Circulation: Heart Failure. 2017. PMID: 29217757. PubMed record
Butler J, Khan MS, Anker SD, et al. Effects of elamipretide on left-ventricular function in patients with heart failure with reduced ejection fraction: PROGRESS-HF. 2020. PMID: 32068002. PubMed record
Ehlers JP, et al. ReCLAIM-2: randomized phase-two trial evaluating elamipretide in age-related macular degeneration. Ophthalmology Science. 2024. PMID: 39605874. PubMed record
Mettu PS, et al. Phase-one clinical trial of elamipretide in dry age-related macular degeneration and non-central geographic atrophy. PMID: 36246181. PubMed record
Campbell MD, Duan J, Samuelson AT, et al. In-vivo mitochondrial ATP production is improved in older adult skeletal muscle after a single dose of elamipretide. 2021. PMID: 34264994. PubMed record
Machiraju P, et al. SS-31 reverses mitochondrial fragmentation in fibroblasts from patients with dilated cardiomyopathy with ataxia. 2019. PMID: 31803760. PubMed record
Medicines and Healthcare products Regulatory Agency. Borderline products: how to tell if your product is a medicine. Updated 2 July 2026. MHRA guidance
Medicines and Healthcare products Regulatory Agency. MHRA Products database. Search authorised UK medicines
Human Medicines Regulations 2012, Regulation 279. UK medicinal-product advertising restriction
World Anti-Doping Agency. 2026 Prohibited List. WADA Prohibited List
International Council for Harmonisation. ICH Q2(R2): Validation of Analytical Procedures. ICH analytical guideline
UK Accreditation Service. Laboratory accreditation and ISO/IEC 17025. UKAS laboratory guidance